Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Careful Administration Re-stressed for Inavir, Relenza in Dairy-Sensitive Patients: Safety Bulletin
The Ministry of Health, Labor and Welfare (MHLW) issued a pharmaceutical safety information bulletin on January 7, re-stressing that physicians should take extra care when using the anti-influenza drugs Inavir (laninamivir) and Relenza (zanamivir) in patients with a history of…
To read the full story
Related Article
- Viekirax Hits Japan Market, MHLW Orders Rare Label Revision upon Listing
November 27, 2015
- Add Type 1 Diabetes to Opdivo Label: MHLW
November 26, 2015
REGULATORY
- Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
May 19, 2026
- Japan to List 1st Biosimilars for Xolair, Ranmark, Simponi on May 20
May 19, 2026
- Japan Provides Stockpiled Avigan to UK for Hantavirus Prevention
May 19, 2026
- 800 More Entities Seek War-Tied Supply Consultation as Future Anxiety Spreads
May 19, 2026
- Japan to Swiftly Consider Safety Measures over Tavneos: Minister
May 19, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…